Abstract
Symptomatic heart failure (HF) affects 4.7 million patients in the U.S. with approximately 550,000 new cases identified annually.1-3 Proportionally, there are 428,000 patients in Canada, incurring $8 billion in annual hospital costs alone, an economic burden expected to double in the next 2 decades.4-6 Other forms of cardiovascular disorders are remaining stable, while the incidence of heart failure is increasing. This is partly the consequence of the successful management of acute heart failure, and partly due to an aging population. The rising prevalence of heart failure is occurring in the context of a persistent one-year mortality rate of between 25 and 40%.5
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ho KK, Pinsky JL, Kannel WB, et al. The Epidemiology of Heart Failure: The Framingham Study. J Am Coll Cardiol. 1993;22:6A–13A.
O’Connell J, Bristow MR. Economic Impact of Heart Failure in the United States: Time for a Different Approach. J Heart Lung Transplant. 1994;13:107–112.
Haldeman GA, Rashidee A, Horswell R. Changes in Mortality from Heart Failure - United States, 1980–1995. Morb Mortal Wkly Rep 1998;47:633–637.
Johansen H, Strauss B, Walsh P, et al. Congestive Heart Failure: The Coming Epidemic. Can Med Assoc J 2002:(in press).
Institute for Clinical Evaluative Sciences (ICES). Cardiovascular Health & Services in Ontario: An ICES Atlas. 1999:111–122.
Liu P, Arnold M, Belenkie I, et al. The 2001 Canadian Cardiovascular Society Consensus Guideline Update for the Management and Prevention of Heart Failure. Can J Cardiol. 2001;12:5E–25E.
Liu P. The Path to Cardiomyopathy: Cycles of Injury, Repair and Maladaptation. Cuit Opin in Cardiol 1996;11:291–292.
Hunter JJ, Chien KR. Signaling Pathways for Cardiac Hypertrophy and Failure. N Engl J Med. 1999;341:1276–1283.
Chien KR. Stress Pathways and Heart Failure. Cell 1999;98:555–558.
MacLellan WR, Schneider MD. Genetic Dissection of Cardiac Growth Control Pathways. Ann Rev Physiol 2000;62:289–319.
Cohn J. The Prevention of Heart Failure-A New Agenda. N Engl J Med.1992;327:725–727.
McKelvie RS, Benedict CR, Yusuf S. Evidence Based Cardiology: Prevention of Congestive Heart Failure and Management of Symptomatic Left Ventricular Dysfunction. British Med J 1999;318:1400–1402.
Morgan HE. Cellular Aspects of Cardiac Failure. Circulation 1993;87:IV4–6.
Francis GS, Chu C. Post-Infarction Myocardial Remodelling: Why Does it Happen? Eur Heart J 1995;16:N31–N36.
Wolfgram LJ, Beisel KW, Herskowitz A, et al. Variations in the Susceptibility to Coxsackievirus B3-Induced Myocarditis Among Different Strains of Mice. J Immunol 1986;136:1846–1852.
Khatib R, Probert A, Reyes MP, et al. Mouse Strain-Related Variation as a Factor in the Pathogenesis of Coxsackievirus B3 Murine Myocarditis. J Gen Virol 1987;68:2981–2988.
Liu P, Mason J. Advances in the Understanding of Myocarditis. Circulation 2001;104:1076–1082.
Traystman MD, Chow LH, McManus BM, et al. Susceptibility to Coxsackievirus B3- Induced Chronic Myocarditis Maps Near the Murine Tcr Alpha and Myhc Alpha loci on Chromosome 14. Am J Pathol 1991;138:721–726.
Gatmaitan BG, Chason JL, Lerner AM. Augmentation of the Virulence of Murine Coxsackievirus B-3 Myocardiopathy by Exercise. J Exp Med 1970;131:1121–1136.
Cabinian AE, Kiel RJ, Smith F, et al. Modification of Exercise-Aggravated Coxsackievirus B3 Murine Myocarditis by T Lymphocyte Suppression in an Inbred Model. J Lab Clin Med 1990;115:454–462.
Chow LH, Gauntt CJ, McManus BM. Differential Effects of Myocarditic Variants of Coxsackievirus B3 in Inbred Mice: A Pathologic Characterization of Heart Tissue Damage. Lab Invest 1991;64:55–64.
Tracy S, Wiegand V, McManus B, et al. Molecular Approaches to Enteroviral Diagnosis in Idiopathic Cardiomyopathy and Myocarditis. J Am Coll Cardiol. Journal of American College 1990;15:1688–1694.
Bergelson JM, Cunningham J A, Droguett G, et al. Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5. Science 1997;275:1320–1323.
Liu P, Aitken K, Kong YY, et al. The Tyrosine Kinase p561ck is Essential in Coxsackievirus B3 Mediated Heart Disease. Nature Med 2000;6:429–434.
Ito M, Kodama M, Masuko M, et al. Expression of Coxsackievirus and Adenovirus Receptor in Hearts of the Rats with Experimental Autoimmune Myocarditis. Circ Res 2000:86:275–280.
Shafren DR, Bates RC, Agrez MV, et al. Coxsackievirus Bl, B3 and B5 Use Decay Accelerating Factor as a Receptor for Cell Attachment. J Virol 1995;69:3873–3877.
Clapman PR, Weiss RA. Immunodeficiency Viruses. Spoilt for Choice of Co- Receptors. Nature 1997;388:230–231.
Martino TA, Petrie M, Brown M, et al. Cardiovirulent Coxsackieviruses and the Decay- Accelerating Factor (CD55) Receptor. Virology 1998;244:302–314.
Martino TA, Liu P, Petrie M, et al. “Enteroviral Myocarditis and Dilated Cardiomyopathy: A Review of Clinical and Experimental Studies.” In Human Enterovirus Infections, Rotbart HA, ed. Washington DC: ASM Press; 1995.
Klingel K, Hohenadl C, Canu A, et al. Ongoing Enterovirus-Induced Myocarditis is Associated with Persistent Heart Muscle Infection: Quantitative Analysis of Virus Replication, Tissue Damage, and Inflammation. Proc Natl Acad Sci 1992;89:314–318.
Opavsky MA, Penninger J, Aitken K, et al. Susceptibility to Myocarditis is Dependent on the Response of alphabeta T Lymphocytes to Coxsackieviral Infection. Circ Res 1999;85:551–558.
Zoller J, Partridge T, Olsen I. Interactions Between Cardiomyocytes and Lymphocytes in Tissue Culture: An In Vitro Model of Inflammatory Heart Disease. J Mol Cell Cardiol 1994;26:627–638.
Seko Y, Matsuda H, Kato K, et al. Expression of Intercellular Adhesion Molecule-1 in Murine Hearts with Acute Myocarditis Caused by Coxsackievirus B3. Journal of Clinical Investigation 1993;91:1327–1336.
Seko Y, Shinkai Y, Kawasaki A, et al. Expression of Perforin in Infiltrating Cells in Murine Hearts with Acute Myocarditis Caused by Coxsackievirus B3. Circulation 1991;84:788–795.
Huber SA, Polgar J, Schultheiss P, et al. Augmentation of Pathogenesis of Coxsackievirus B3 Infections in Mice by Exogenous Administration of Interleukin-1 and Interleukin-2. J Virol 1994;68:195–206.
Huber SA, Pfaeffle B. Differential Thl and Th2 Cell Responses in Male and Female BALB/c Mice Infected with Coxsackievirus Group B Type 3. J Virol 1994;68:5126–5132.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Nian, M., Opavsky, A., Arnold, M., Liu, P. (2003). Registry of Myocarditis and Heart Failure. In: Matsumori, A. (eds) Cardiomyopathies and Heart Failure. Developments in Cardiovascular Medicine, vol 248. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9264-2_30
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9264-2_30
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4865-8
Online ISBN: 978-1-4419-9264-2
eBook Packages: Springer Book Archive